Physician profile
Marcel A Bavoux
NPI 1508990557
$2,874.35
in general payments reported to CMS, 2019-2025
30 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $390 · 2021: $88.38 · 2022: $18.42 · 2024: $120 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $548.57 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $398.64 | 2019-2025 | |
| Pfizer INC. | $337.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.28 | 2019 | |
| Genentech USA, INC. | $140.07 | 2019-2020 | |
| Amgen INC. | $125.44 | 2019-2025 | Evenity |
| Glaxosmithkline, LLC. | $118.73 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $97.57 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $91.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.78 | 2019-2020 | |
| Amarin Pharma, INC. | $83.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.93 | 2019-2020 | |
| Melinta Therapeutics, LLC | $69.10 | 2019 | |
| Exact Sciences Corporation | $68.46 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $62.44 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $44.35 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $35.83 | 2019 | |
| Tonix Medicines, INC. | $33.60 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $32.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.23 | 2019-2020 | |
| Antares Pharma, INC. | $28.41 | 2025 | Xyosted |
| Lundbeck LLC | $27.31 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $25.60 | 2025 | Gemtesa |
| Shire North American Group INC | $23.14 | 2019 | |
| Novo Nordisk INC | $21.00 | 2019 | |
| Mylan Specialty L.P. | $17.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2025 | Zoryve |
| Gilead Sciences, INC. | $16.73 | 2019 | |
| Sanofi Pasteur INC. | $16.71 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Bavoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.